Axa S.A. Purchases Shares of 1,824,685 Autolus Therapeutics plc (NASDAQ:AUTL)

AXA S.A. acquired a new stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,824,685 shares of the company's stock, valued at approximately $4,288,000. AXA S.A. owned about 0.69% of Autolus Therapeutics as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in shares of Autolus Therapeutics in the fourth quarter valued at approximately $26,000. Barclays PLC grew its position in Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after buying an additional 10,866 shares during the last quarter. Dumont & Blake Investment Advisors LLC acquired a new position in Autolus Therapeutics in the 4th quarter valued at $35,000. Arkadios Wealth Advisors purchased a new position in Autolus Therapeutics during the 4th quarter worth $47,000. Finally, Daiwa Securities Group Inc. lifted its stake in shares of Autolus Therapeutics by 55.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after acquiring an additional 8,479 shares during the period. 72.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AUTL has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Truist Financial dropped their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, Wells Fargo & Company cut their target price on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 21st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Stock Performance

AUTL traded down $0.08 on Tuesday, hitting $1.27. 1,729,070 shares of the company were exchanged, compared to its average volume of 1,461,786. Autolus Therapeutics plc has a fifty-two week low of $1.11 and a fifty-two week high of $5.00. The firm has a market capitalization of $338.00 million, a P/E ratio of -1.05 and a beta of 1.77. The business's fifty day moving average is $1.51 and its 200 day moving average is $2.21.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $8.98 million during the quarter, compared to analyst estimates of $1.59 million. Analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.